Low-cost method to store, transport life-saving vaccines developed

Toronto: Scientists have developed a low-cost method to store crucial vaccines for weeks at a time, paving the way for safely transporting them to remote and developing regions of the world. According to scientists at the McMaster University in Canada, the research can replace the cumbersome "cold chain" -- constant storage at temperatures between two and eight degrees Celsius -- currently necessary to keep anti-viral vaccines viable.
Regions lacking the infrastructure to refrigerate and transport vaccines could possibly benefit from this, they said.
"You can spend all kinds of money developing a vaccine, but if it is deactivated by high temperature an hour before you can give it to someone, it doesn't matter," said Ali Ashkar, a professor at the McMaster University.
Read Also: CDSCO rejects GSK request to skip Phase III trial for Influenza Vaccine for higher age groups
The new method, described in the journal Scientific Reports, combines ingredients in existing vaccines with a sugary gels, remaining viable for eight weeks or more, even at elevated temperatures.
According to the researchers, only the marginal cost of preparing the vaccine would be added up while eliminating almost all the transportation cost which accounts for 80 per cent of the total cost of inoculation.
Combining the vaccines and the sugars -- pullulan and trehalose -- is almost as simple as stirring cream and sugar into coffee, the researchers said.
Read Also: Vaccines saving millions in Somalia: Urgent need to scale up routine immunisation programme
The storage technology was initially used to demonstrate effectiveness in other applications -- prolonging the shelf life of fruits and vegetables using an edible coating.
Not being able to get vaccines to isolated areas makes it difficult to eradicate deadly viruses, devastating local populations and reaching exposed pockets in more populated countries.
Religious, cultural or other concerns in such regions have diminished the proportion of vaccinated individuals, researchers said.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd